Hotlist vs the FDA's Prohibited and Restricted List

A brand owner emailed me last month convinced her formula was fine for Canada because "the FDA already cleared it." The FDA does not clear cosmetic formulas at all, and even setting that aside, the two countries do not ban the same things. She had one ingredient at a level that was perfectly legal in the US and outright prohibited north of the border.

Two very different list philosophies

The US approach to cosmetic ingredient safety is comparatively narrow. Under the framework FDA operates within, cosmetics are not subject to premarket approval the way drugs are, and the list of substances FDA specifically prohibits or restricts in cosmetics is short. MoCRA, the 2022 law that reshaped US cosmetic oversight, added facility registration, product listing, a named responsible person, safety substantiation, and adverse event recordkeeping. It did not hand FDA a long ingredient blacklist to enforce ingredient by ingredient the way some other regulators maintain.

Health Canada's Cosmetic Ingredient Hotlist is a different animal. It is a working document that names substances prohibited outright, and separately lists substances that are restricted to a maximum concentration, a specific use, or conditions like required warnings. It gets updated more often and covers considerably more ground than the US prohibited/restricted list, partly because Canada has historically aligned parts of its cosmetic ingredient policy with international norms that go beyond the US baseline.

Why "FDA-compliant" isn't a passport

Here's the practical trap. A formula built for the US market, checked only against US rules, can contain:

• An ingredient at a concentration that is unrestricted in the US but capped on the Hotlist.
• A preservative or colorant permitted broadly in the US but restricted to specific product types in Canada.
• A fragrance component that needs allergen disclosure in Canada under the incoming List 1 and List 2 requirements, with no equivalent trigger in current US labeling practice.

None of that shows up if you only run a US-lens check. The formula "passing" FDA scrutiny really just means you have not violated the narrower list FDA maintains and you are handling registration, listing, and safety substantiation under MoCRA. It says nothing about Health Canada's Hotlist.

What actually needs checking for each market

Step	United States (MoCRA)	Canada (Cosmetic Regulations)
Premarket step	Facility registration + product listing	Cosmetic Notification Form (CNF), a notification not an approval
Ingredient screening	Short FDA prohibited/restricted list	Cosmetic Ingredient Hotlist (prohibited and restricted, more entries)
Responsible party	Named responsible person	Notifier of record on the CNF
Labeling	English, US-specific requirements	Bilingual, English and French
Timing	Registration/listing per MoCRA timelines	CNF due within 10 days of first sale

A worked example

Say you are launching a brightening serum with an ingredient that both markets allow, but at different levels, plus a fragrance blend containing linalool and limonene. In the US today, that fragrance blend mostly just needs to be accurate on the ingredient list. In Canada, once List 1 becomes mandatory on the CNF and label on April 12, 2026, and List 2 follows on August 1, 2026, those allergens need disclosure above 0.001% in a leave-on product. If your US label was your only reference point, you would miss that entirely.

The practical move

Treat every market as its own screen, not a variation on the one you already did. Map every ingredient to its INCI name and CAS number, because trade names and blend names hide what you actually need to check. Then run that INCI list against each market's actual restricted substance list rather than assuming one clean pass covers you everywhere.

This is the exact workflow Cosmetic Comply automates for the Canadian side today, matching your ingredients to INCI and CAS, screening against the Hotlist with a confidence score, and having a real reviewer confirm before filing your CNF. US, EU, and Australia screening are on the way, but the underlying lesson holds regardless of which tool you use: a pass in one country's system is not evidence of anything in another's.